Sinovac Biotech (SVA) Tops Q4 EPS by 1c

Sinovac Biotech (NASDAQ: SVA) reported Q4 EPS of $0.02, $0.01 better than the analyst estimate of $0.01. Revenue for the quarter came in at $22.9 million versus the consensus estimate of $14.1 million.

For earnings history and earnings-related data on Sinovac Biotech (SVA) click here.

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• Community West Bancshares (CWBC) Tops Q1 EPS by 7c
• Endexx Corporation (EDXC) Reports Q1 Loss of $0.01